ArticleGeroScience2026
Exploring TIMP2 genetics and CSF levels in Parkinson's disease: biomarkers of neurodegeneration and ageing.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeMatrix metalloproteinases (MMPs) regulate extracellular matrix remodeling and are implicated in neurodegeneration and brain ageing. Tissue inhibitor of metalloproteinase-2 (TIMP2) has been associated with hippocampal plasticity and cognitive function. We investigated whether cerebrospinal fluid (CSF) TIMP2 levels and genetic variants are associated with clinical features in Parkinson's disease (PD) and its continuum with dementia with Lewy bodies (DLB), with a particular focus on ageing-related processes.
methodsCSF TIMP2 levels were analyzed in 480 patients with PD, 67 patients with DLB and 16 control participants. PD patients were stratified by GBA1 mutation status. Cross-sectional analyses included clinical scales and established CSF biomarkers (β-amyloid 1-42, h-TAU, p-TAU, neurofilament light chain (NfL) and α-synuclein). Longitudinal analyses assessed cognitive impairment and motor progression using TIMP2 tertiles and selected single nucleotide polymorphisms (SNPs) within the TIMP2 gene.
resultsCSF TIMP2 levels were positively associated with age and correlated with markers of neurodegeneration. Higher levels were observed in male PD patients compared to females and in female DLB GBA1 patients compared to controls. TIMP2 levels were not significantly associated with incidence or time to cognitive impairment. Higher TIMP2 levels were linked to increased postural instability in PD GBA1 patients. Exploratory genetic analyses suggested that specific SNPs (rs1384364, rs8068674) were associated with more favorable cognitive outcomes or delayed motor progression.
conclusionsCSF TIMP2 levels primarily reflect ageing-related processes associated with neurodegeneration rather than disease-specific effects. Genetic variation in TIMP2 may contribute to clinical heterogeneity. These findings support a role of extracellular matrix-related ageing mechanisms in PD and related disorders.
Indexed as
Identifiers
42730910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.